StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a report released on Tuesday. The brokerage issued a sell rating on the stock.
Bio-Path Trading Up 2.7 %
Shares of BPTH stock opened at $0.84 on Tuesday. The business’s 50 day moving average is $0.89 and its two-hundred day moving average is $1.11. Bio-Path has a 12 month low of $0.59 and a 12 month high of $9.99.
Institutional Investors Weigh In On Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC purchased a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. 5.74% of the stock is owned by institutional investors and hedge funds.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- What Is WallStreetBets and What Stocks Are They Targeting?
- SAP’s Strong Momentum: A Bullish Setup for Investors
- How to Invest in Small Cap Stocks
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- What is the Dogs of the Dow Strategy? Overview and Examples
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
